Efficacy of Ixekizumab vs. Adalimumab in Psoriatic Arthritis and Psoriasis
Dermatology summaries collection focusing on a study comparing the efficacy and safety of ixekizumab and adalimumab in biologic-naive patients with active psoriatic arthritis and moderate-to-severe psoriasis. Results from the SPIRIT-H2H trial are discussed, highlighting the superior effectiveness of ixekizumab up to Week 52.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
INFODERMATOLOGY SUMMARIES Focus sulla psoriasi Un servizio di aggiornamento scientifico sostenuto da un contributo educazionale non condizionante di
Dermatology summaries collection Dalla lettura internazionale | Focus sulla psoriasi Efficacy and safety of ixekizumab versus adalimumab in biologic-na ve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial Kristian Reich, Lars Erik Kristensen, Saxon D Smith, Phoebe Rich, Christophe Sapin, Soyi Liu Leage, Robert McKenzie, Christopher Schuster, Elisabeth Riedl, Melinda Gooderham Dermatol Pract Concept. 2022 Apr 1;12(2):e2022104 Background & methods Results Conclusions Messaggi chiave 2 Un servizio di aggiornamento scientifico sostenuto da un contributo educazionale non condizionante di 2
Focus sulla psoriasi Messaggi chiave Lo studio randomizzato, in aperto, in cieco, a gruppi paralleli SPIRIT-H2H ha dimostrato la superiorit di ixekizumab su adalimumab nel raggiungimento simultaneo dei sintomi articolari (ACR50) e della clearance cutanea (PASI 100) in pazienti na ve ai biologici con artrite psoriasica attiva e psoriasi a placche alla settimana 24. Una maggiore efficacia di ixekizumab rispetto ad adalimumab stata mantenuta fino alla settimana 52. 3 Developed by 3
Focus sulla psoriasi Introduction The randomized, open-label, assessor-blinded, parallel-group SPIRIT-H2H trial (NCT03151551) demonstrated superiority of ixekizumab over adalimumab in simultaneously achieving improvement in joint symptoms (American College of Rheumatology [ACR]50) and skin clearance (Psoriasis Area and Severity Index [PASI]100) in biologic-na ve patients with active psoriatic arthritis (PsA) and plaque psoriasis (PsO) at Week (W) 24. Higher efficacy of ixekizumab versus adalimumab was maintained through W52. 4 Developed by 4
Focus sulla psoriasi Objectives This analysis investigated efficacy and safety of ixekizumab and adalimumab in the subgroup of patients with PsA and moderate-to-severe PsO through W52. 5 Developed by 5
Focus sulla psoriasi Methods Efficacy and safety outcomes were analyzed in patients with PsA and moderate-to-severe PsO (PASI 12, Body Surface Area 10%, static Physician Global Assessment 3) through W52. Categorical and continuous outcomes were analyzed using logistic regression models and mixed model for repeated measures, respectively. 6 Developed by 6
Focus sulla psoriasi Results More ixekizumab-versus adalimumab-treated patients simultaneously achieved PASI100 and ACR50 at W24 (40.8% versus 17.6%, p = 0.015) and W52 (38.8% versus 17.6%, p = 0.026). Likewise, more ixekizumab-versus adalimumab-treated patients achieved PASI100 (59.2% versus 25.5%, p = 0.001) and PASI90 (81.6% versus 60.8%, p = 0.028) through W52, and nail PsO clearance at W24. Joint symptom improvements were comparable between groups. No new safety findings were reported. 7 Developed by 7
Focus sulla psoriasi Conclusion Ixekizumab had higher efficacy than adalimumab in simultaneous achievement of ACR50 and PASI100 at W24 and W52 in patients with PsA and moderate-to-severe PsO. Ixekizumab-treated patients showed higher response rates for nail PsO clearance and for reporting minimal or no impact on quality of life at W24. 8 Developed by 8
INFODERMATOLOGY SUMMARIES Focus sulla psoriasi Un servizio di aggiornamento scientifico sostenuto da un contributo educazionale non condizionante di
